Pavunalimab

{
  "id": "MLC-T-ONC-015866",
  "term": "Pavunalimab",
  "field": "Oncology and biomedicine",
  "definition": "An Fc-engineered bispecific antibody directed against the human negative immunoregulatory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4) and lymphocyte activation gene 3 protein (LAG3; LAG-3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bavunalimab targets and binds to both CTLA-4 and LAG-3 expressed on T cells in the tumor microenvironment (TME). Both CTLA-4 and LAG-3 are inhibitory receptors and members of the immunoglobulin superfamily (IgSF); they are overexpressed by regulatory T cells (Tregs) in the TME where they downregulate T-cell activation and proliferation. Dual checkpoint blockade of CTLA-4 and LAG-3 with XmAb22841 may enhance T-cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. The engineered Fc domain increases the stability and half-life of the antibody.",
  "synonyms": [
    "anti-CTLA-4/anti-LAG-3 bispecific monoclonal antibody XmAb22841",
    "CTLA-4xLAG-3 bispecific antibody XmAb22841",
    "anti-CTLA-4/LAG-3 bispecific antibody XmAb22841",
    "CTLA-4 x LAG-3 bispecific antibody XmAb22841"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pavunalimab/"
}